Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
BMC Public Health ; 19(1): 826, 2019 Jun 26.
Article in English | MEDLINE | ID: mdl-31242875

ABSTRACT

BACKGROUND: Varicella is a highly contagious childhood disease. Generally benign, serious complications necessitating antibiotic use may occur. The objective of this study was to characterize the rate, appropriateness and patterns of real-world antibiotic prescribing for management of varicella-associated complications, prior to universal varicella vaccination (UVV) implementation. METHODS: Pooled, post-hoc analysis of 5 international, multicenter, retrospective chart reviews studies (Argentina, Hungary, Mexico, Peru, Poland). Inpatient and outpatient primary pediatric (1-14 years) varicella cases, diagnosed between 2009 and 2016, were eligible. Outcomes, assessed descriptively, included varicella-associated complications and antibiotic use. Three antibiotic prescribing scenarios were defined based on complication profile in chart: evidence of microbiologically confirmed bacterial infection (Scenario A); insufficient evidence confirming microbiological confirmation (Scenario B); no evidence of microbiological confirmation (Scenario C). Stratification was performed by patient status (inpatient vs. outpatient) and country. RESULTS: Four hundred one outpatients and 386 inpatients were included. Mean (SD) outpatient age was 3.6 (2.8) years; inpatient age was 3.1 (2.8) years. Male gender was predominant. Overall, 12.2% outpatients reported ≥1 infectious complication, 3.7% ≥1 bacterial infection, and 0.5% ≥1 microbiologically confirmed infection; inpatient complication rates were 78.8, 33.2 and 16.6%, respectively. Antibiotics were prescribed to 12.7% of outpatients and 68.9% of inpatients. Among users, ß-lactamases (class), and clindamycin (agent), dominated prescriptions. Scenario A was assigned to 3.9% (outpatients) vs 13.2% (inpatients); Scenario B: 2.0% vs. 6.0%; Scenario C: 94.1% vs. 80.8%. CONCLUSIONS: High rates of infectious complications and antibiotic use are reported, with low rates of microbiological confirmation suggesting possible antibiotic misuse for management of varicella complications.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Chickenpox/drug therapy , Delivery of Health Care/standards , Drug Prescriptions/statistics & numerical data , Adolescent , Bacterial Infections/drug therapy , Bacterial Infections/microbiology , Chickenpox/epidemiology , Chickenpox/virology , Child , Child, Preschool , Clindamycin/therapeutic use , Europe/epidemiology , Female , Hospitalization , Humans , Infant , Inpatients , Latin America/epidemiology , Male , Outpatients , Retrospective Studies , beta-Lactamases/therapeutic use
2.
Rev. méd. hered ; 30(2): 76-86, abr. 2019. graf, tab
Article in Spanish | LILACS, LIPECS | ID: biblio-1058672

ABSTRACT

Objetivo: Describir las complicaciones más frecuentes y la carga económica asociada con la varicela en el Perú. Material y métodos: Estudio multicéntrico de revisión de historias clínicas de pacientes de 1 a 14 años con diagnóstico de varicela entre 2011 y 2016. El uso de recursos de atención médica (URAM) asociados con la varicela, los costos unitarios y la pérdida de trabajo se utilizaron para estimar los costos directos e indirectos, presentados en USD ($). Los datos de costos y URAM se combinaron con estimaciones de carga de enfermedad para calcular el costo total anual de la varicela en el Perú. Resultados: Se incluyeron un total de 179 niños con varicela (101 ambulatorios, 78 hospitalizados). Entre los pacientes ambulatorios, el 5,9 % presentó una o más complicaciones, en comparación con 96,2 % de pacientes hospitalizados. El URAM incluyó el uso de medicamentos de venta libre (72,3 % frente a 89,7 % de pacientes ambulatorios y hospitalizados, respectivamente), medicamentos con receta (30,7 % frente a 94,9 %) y análisis y procedimientos (0,0 % frente a 80,8 %). Los costos directos e indirectos por caso ambulatorio fueron $36 y $62 respectivamente y por caso hospitalizado fueron $548 y $222. El costo anual total asociado con la varicela se estimó en $13 907 146. Conclusión: La varicela está asociada con complicaciones clínicas importantes y elevado URAM en Perú, lo que respalda la necesidad de implementación de un plan de vacunación universal. (AU)


Objective: The purpose of this study was to evaluate the clinical and economic burden associated with varicella in Peru. Methods: This was a multicenter, retrospective chart review study of patients aged 1-14 years with a varicella diagnosis between 2011 and 2016. Healthcare resource utilization (HCRU) associated with varicella, unit costs, and work loss were used to estimate direct and indirect costs, presented in USD ($). The cost and HCRU data was combined with estimates of varicella disease burden to estimate the overall annual costs of management of varicella in Peru. Results: A total of 179 children with varicella (101 outpatients, 78 inpatients) were included. Among outpatients, 5.9% experienced ≥1 complication, compared with 96.2% of inpatients. HCRU estimates included use of over-the-counter (OTC) medications (72.3% vs. 89.7% of outpatient and inpatients, respectively), prescription medications (30.7% vs. 94.9%), tests/procedures (0.0% vs. 80.8%). Among outpatients, direct and indirect costs per case were $36 and $62, respectively; among inpatients, respective costs were $548 and $222. The total annual cost associated with varicella was estimated at $ 13 907 146. Conclusion: Varicella is associated with substantial clinical complications and high HCRU in Peru, supporting the need for implementation of a routine childhood varicella vaccination plan. (AU)


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Peru , Chickenpox/economics , Health Care Costs , Health Expenditures , Immunization Programs , Costs and Cost Analysis , Retrospective Studies , Multicenter Studies as Topic , Observational Studies as Topic
3.
Hum Vaccin Immunother ; 15(4): 932-941, 2019.
Article in English | MEDLINE | ID: mdl-30681397

ABSTRACT

Varicella is a mild and self-limited illness in children, but can result in significant healthcare resource utilization (HCRU). To quantify/contrast varicella-associated HCRU in five middle-income countries (Hungary, Poland, Argentina, Mexico, and Peru) where universal varicella vaccination was unimplemented, charts were retrospectively reviewed among 1-14 year-olds. Data were obtained on management of primary varicella between 2009-2016, including outpatient/inpatient visits, allied healthcare contacts, tests/procedures, and medications. These results are contrasted across countries, and a regression model is fit to extrapolated country-level costs as a function of gross domestic product (GDP). A total of 401 outpatients and 386 inpatients were included. Significant differences between countries were observed in the number of skin lesions among outpatients, ranging from 5.3% to 25.4% of patients with ≥250 lesions. Among inpatients, results were less variable. Average ambulatory medical visits ranged from 1.1 to 2.2. Average hospital stay ranged from 3.6 to 6.8 days. Use of tests/procedures was infrequent in outpatients, except in Argentina (13.3%); among inpatients, a test/procedure was ordered for 81.3% of patients, without regional variation. Prescription medications were administered in 44.4% of outpatients (range 9.3%-80.0%), and in 86% of inpatients (range 70.4%-94.9%). Total estimated spending on varicella treatment in the absence of vaccination was predicted from income levels (GDP) with an exponential function (R2 = 0.89). This study demonstrates that substantial HCRU is associated with varicella resulting in significant public health burden that could be alleviated through the use of varicella vaccination. Differences observed between countries possibly reflect treatment guidelines, healthcare resource availabilities and physician practices.


Subject(s)
Chickenpox/economics , Cost of Illness , Developing Countries/economics , Developing Countries/statistics & numerical data , Patient Acceptance of Health Care/statistics & numerical data , Vaccination/economics , Adolescent , Chickenpox/drug therapy , Chickenpox/prevention & control , Child , Child, Preschool , Europe , Female , Health Resources , Humans , Infant , Latin America , Male , Outpatients , Retrospective Studies , Vaccination/legislation & jurisprudence
4.
BMC Infect Dis ; 19(1): 75, 2019 Jan 21.
Article in English | MEDLINE | ID: mdl-30665366

ABSTRACT

BACKGROUND: Acute respiratory infections (ARIs) represent an important cause of morbidity and mortality in children, remaining a major public health concern, especially affecting children under 5 years old from low-income countries. Unfortunately, information regarding their epidemiology is still limited in Peru. METHODS: A secondary data analysis was performed from a previous cross-sectional study conducted in children with a probable diagnosis of Pertussis from January 2010 to July 2012. All samples were analyzed via Polymerase Chain Reaction (PCR) for the following etiologies: Influenza-A, Influenza-B, RSV-A, RSV-B, Adenovirus, Parainfluenza 1 virus, Parainfluenza 2 virus, Parainfluenza 3 virus, Mycoplasma pneumoniae and Chlamydia pneumoniae. RESULTS: A total of 288 patients were included. The most common pathogen isolated was Adenovirus (49%), followed by Bordetella pertussis (41%) from our previous investigation, the most prevelant microorganisms were Mycoplasma pneumonia (26%) and Influenza-B (19.8%). Coinfections were reported in 58% of samples and the most common association was found between B. pertussis and Adenovirus (12.2%). CONCLUSIONS: There was a high prevalence of Adenovirus, Mycoplasma pneumoniae and other etiologies in patients with a probable diagnosis of pertussis. Despite the presence of persistent cough lasting at least two weeks and other clinical characteristics highly suspicious of pertussis, secondary etiologies should be considered in children under 5 years-old in order to give a proper treatment.


Subject(s)
Respiratory Tract Infections/microbiology , Respiratory Tract Infections/virology , Whooping Cough/etiology , Adenoviridae Infections/epidemiology , Adenoviridae Infections/etiology , Bordetella pertussis/genetics , Bordetella pertussis/isolation & purification , Child, Preschool , Chlamydophila Infections/epidemiology , Chlamydophila Infections/etiology , Chlamydophila pneumoniae/genetics , Chlamydophila pneumoniae/isolation & purification , Cough/microbiology , Cross-Sectional Studies , Female , Hospitalization , Humans , Infant , Infant, Newborn , Influenza, Human/epidemiology , Influenza, Human/etiology , Male , Mycoplasma pneumoniae/isolation & purification , Parainfluenza Virus 3, Human/genetics , Parainfluenza Virus 3, Human/isolation & purification , Peru/epidemiology , Pneumonia, Mycoplasma/epidemiology , Pneumonia, Mycoplasma/microbiology , Respiratory Tract Infections/epidemiology , Respirovirus Infections/epidemiology , Respirovirus Infections/etiology , Whooping Cough/diagnosis , Whooping Cough/epidemiology
5.
Int J Infect Dis ; 41: 36-41, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26523641

ABSTRACT

OBJECTIVES: To report the incidence, epidemiology, and clinical features of Bordetella pertussis in Peruvian infants under 1 year old. PATIENTS AND METHODS: A prospective cross-sectional study was conducted in five hospitals in Peru from January 2010 to July 2012. A total of 392 infants under 1 year old were admitted with a clinical diagnosis of whooping cough and tested for B. pertussis by PCR. RESULTS: The pertussis toxin and IS481 genes were detected in 39.54% (155/392) of the cases. Infants aged less than 3 months were the most affected, with a prevalence of 73.55% (114/155). The most common household contact was the mother, identified in 20% (31/155) of cases. Paroxysm of coughing (89.03%, 138/155), cyanosis (68.39%, 106/155), respiratory distress (67.09%, 104/155), and breastfeeding difficulties (39.35%, 61/155) were the most frequent symptoms reported. CONCLUSION: An increase in pertussis cases has been reported in recent years in Peru, despite national immunization efforts. Surveillance with PCR for B. pertussis is essential, especially in infants less than 1 year old, in whom a higher rate of disease-related complications and higher mortality have been reported.


Subject(s)
Bordetella pertussis/genetics , Whooping Cough/epidemiology , Whooping Cough/prevention & control , Cross-Sectional Studies , Female , Hospitals , Humans , Immunization , Infant , Infant, Newborn , Male , Pertussis Vaccine/immunology , Peru/epidemiology , Polymerase Chain Reaction , Prevalence , Vaccination , Whooping Cough/diagnosis , Whooping Cough/microbiology
6.
J Nanosci Nanotechnol ; 5(1): 140-5, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15762172

ABSTRACT

The loculate ("chambered") valve structure of centric diatoms like Triceratium favus Ehrenberg has been mentioned time and again in the nanostructure literature. Here we draw attention to the fundamentally different alternative sandwich model nature developed in the genus Pleurosigma, where it is nonloculate. This has so far been overlooked in nanostructural studies. We suggest some mechanical aspects that would offer interesting avenues for experimental testing. The first description of the natural fabrication process ("morphogenesis") is presented. This begins with the development of the raphe sternum, which then acts as a rigid backbone. The inner layer of the sandwich-structured valve develops next, with relatively large +/- round single internal foramina not yet closed by a sieve membrane, in offset arrangement. This serves as a substrate for rows of stubby hollow pillars, also in offset arrangement. Then the outer layer of the sandwich develops and two different patterns ("coarse-mesh" and "stellate bridges") have been observed. At first, the external areolar foramina are relatively large and +/- oval, gradually filling up until the tiny slits characteristic of the genus remain. In Pleurosigma species with double internal areolar foramina, small bridges grow from the opposite margins of the single foramina until they fuse. The sieve-membranes then close the internal areolar foramina. The finished valve is a lightweight structure expected to offer excellent strength with parsimonious expenditure of the raw material-silica.


Subject(s)
Biomimetics/methods , Cell Membrane/physiology , Cell Membrane/ultrastructure , Diatoms/cytology , Diatoms/growth & development , Morphogenesis/physiology , Nanotechnology/methods , Cell Adhesion/physiology , Diatoms/classification , Species Specificity , Surface Properties
7.
Folia dermatol. peru ; 8(4): 30-8, dic. 1997. ilus
Article in Spanish | LILACS | ID: lil-289457

ABSTRACT

El presente trabajo describe la forma de presentación clínica, laboratorio y respuesta al tratamiento con itraconazol de la paracoccidioidomicosis en cuatro niños hospitalizados en el Instituto de Salud del Niño entre los años de 1990 y 1997. Todos los pacientes presentaron la forma diseminada de la enfermedad . La sintomatología más frecuente fue fiebre y linfadenopatías tanto supeficiales como intrabdominales y compromiso gastrointestinal caracterizado por diarrea disentérica. Uno de ellos tuvo diagnóstico de tuberculosis pulmonar probable. El examen directo de aspirado ganglionar con KOH al 10 por ciento, por ser de fácil acceso, rápido y por tener una sensibilidad que llega al 100 por ciento, fue la prueba diagnóstica de elección. La respuesta al tratamiento y tolerancia al itraconazol fueron buenas.


Subject(s)
Humans , Male , Female , Itraconazole/therapeutic use , Paracoccidioidomycosis/complications , Paracoccidioidomycosis/therapy
8.
Diagnóstico (Perú) ; 20(1): 29-31, jul. 1987.
Article in Spanish | LILACS, LIPECS | ID: lil-64422

ABSTRACT

Se reporta un caso de Meningoencefalitis neonatal a Salmonela, ocurrido en un niño de 4 dias de edad, nacido en un Centro Hospitalario, con un peso de 4,250 g. y 52 cm. de talla, quién presentó sintomatología precoz, caracterizada por diarrea, vómitos y fiebre desde el cuarto día de nacida, convulsisonando al sexto. El cultivo del líquido céfalo raquídeo demostró Salmonela Grupo I Enteriditis. A pesar del tratamiento la evolución fue desfavorrable, falleciendo a los cuarenticinco dias de hospitalización. Recibió como tratamiento antibiótico: Penicilina, Cloranfenicol, Ampicilina, Amicacina, Cefalosporina (Cefotaxima). Se comenta el riesgo de la Salmonela como condicionante de infecciones sistémicas severas en el neonato, el problema de la prevalencia del gérmen en nuestros Hospitales y su resistencia antibiótica


Subject(s)
Infant, Newborn , Humans , Male , Salmonella enteritidis , Salmonella Infections/complications , Meningoencephalitis/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...